ANTIDEPRESSANT TREATMENT PATTERNS, HEALTH CARE UTILIZATION AND COST AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

被引：0
|
作者：
Isenberg, K. [1 ]
Eisenberg, D. [2 ]
Sanchez, R. [3 ]
Alvir, J. [3 ]
Wang, J. [4 ]
Gu, T. [2 ]
White, J. [4 ]
机构：
[1] Blue Cross Blue Shield Missouri, Kansas City, MO USA
[2] HealthCore Inc, Wilmington, DE USA
[3] Pfizer Inc, New York, NY USA
[4] WellPoint Inc, Thousand Oaks, CA USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.486
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A89 / A89
页数：1
相关论文
共 50 条
  • [31] Inadequate Response to Antidepressant Treatment in Major Depressive Disorder
    Papakostas, George I.
    Jackson, W. Clay
    Rafeyan, Roueen
    Trivedi, Madhukar H.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2020, 81 (03)
  • [32] TRANSCRANIAL MAGNETIC STIMULATION (TMS) IN SLEEP QUALITY AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
    Schaffer, Daniel R.
    Nason, Samantha
    Neumann, Serina
    [J]. ANNALS OF BEHAVIORAL MEDICINE, 2018, 52 : S763 - S763
  • [33] Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder
    Naudet, Florian
    Boussageon, Remy
    Palpacuer, Clement
    Gallet, Laurent
    Reymann, Jean-Michel
    Falissard, Bruno
    [J]. THERAPIE, 2015, 70 (04): : 321 - 327
  • [34] Superiority of Escitalopram over Paroxetine in the treatment of Major Depressive Disorder (MDD)
    Kasper, S.
    Baldwin, D.
    Boulenger, J. P.
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (04) : 337 - 337
  • [35] Erratum to: Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)
    Katelyn R. Keyloun
    Ryan N. Hansen
    Zsolt Hepp
    Patrick Gillard
    Michael E. Thase
    Emily Beth Devine
    [J]. CNS Drugs, 2017, 31 : 511 - 511
  • [36] Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder
    Kohler-Forsberg, Ole
    Larsen, Erik Roj
    Buttenschon, Henriette N.
    Rietschel, Marcella
    Hauser, Joanna
    Souery, Daniel
    Maier, Wolfgang
    Farmer, Anne
    McGuffin, Peter
    Aitchison, Katherine J.
    Uher, Rudolf
    Mors, Ole
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2019, 215 (02) : 494 - 501
  • [37] Efficacy and safety of sertraline in the treatment of pediatric major depressive disorder (MDD)
    Wagner, K
    Donnelly, C
    Wohlberg, C
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S231 - S232
  • [38] COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS AS ADJUNCTIVE THERAPY IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
    Taneja, C.
    Oster, G.
    Jing, Y.
    Baker, R. A.
    Forbes, R. A.
    Papakostas, G., I
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A113 - A113
  • [39] Duloxetine versus placebo in patients with major depressive disorder (MDD): assessment of energy and vitality in MDD
    Myers-Oakes, T. M.
    Thase, M. E.
    Meyers, A. L.
    Ahl, J.
    Prakash, A.
    Marangell, L. B.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S425 - S426
  • [40] Treatment Costs in Secondary and Tertiary Mental Health Care in Patients with Major Depressive Disorder
    Kan, Kaying
    Lokkerbol, Joran
    Jorg, Frederike
    Visser, Ellen
    Schoevers, Robert
    Feenstra, Talitha
    [J]. JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2017, 20 : S18 - S18
12345